Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-22T17:59:46.240Z Has data issue: false hasContentIssue false
  • English
  • Français

Active and Passive Avoidance Learning in Controls and Schizophrenic Patients on Racemic Propranolol and Neuroleptics

Published online by Cambridge University Press:  29 January 2018

John Gruzelier ,
Susan Thornton ,
David Staniforth ,
Saniha Zaki  and
Neil Yorkston
John Gruzelier
Affiliation:
Department of Psychiatry, Charing Cross Hospital Medical School, Fulham Palace Road, London W6 8RF The Neuropsychology Research Unit, Friern Hospital and University College Hospital Medical School
Susan Thornton
Affiliation:
The Neuropsychology Research Unit, Friern Hospital and University College Hospital Medical School
David Staniforth
Affiliation:
The Neuropsychology Research Unit, Friern Hospital and University College Hospital Medical School
Saniha Zaki
Affiliation:
Friern Hospital, London, N18
Neil Yorkston
Affiliation:
Bethlem Royal and Maudsley Hospitals, London SE5
Get access Rights & Permissions [Opens in a new window]

Summary

Normal controls and schizophrenic patients on propranolol as sole drug or combined with neuroleptics showed superior active and passive avoidance learning to schizophrenic patients who were medicated with conventional neuroleptics only. Active avoidance involved responding quickly, passive avoidance withholding a response to avoid an unpleasant noise and reacting to the appropriate stimulus. This may reflect an improvement brought about by propranolol in the limbic regulation of stimulus and response processes.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 137 , Issue 2 , August 1980 , pp. 131 - 137
Copyright
Copyright © Royal College of Psychiatrists, 1980 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Atsmon, A. & Blum, I. (1978) The discovery. In Propranolol and Schizophrenia (eds. Roberts, E. and Amacher, P.). New York: A. R. Liss, pp 5–38.Google Scholar
Bignami, G. (1978) Effects of neuroleptics, ethanol, hypnotic-sedatives, tranquilizers, narcotics and minor stimulants in aversive paradigms. In Psychopharmacology of Aversively Motivated Behaviour (eds. Anisman, H. and Bignami, G.). New York: Plenum Press.Google Scholar
Davison, M. A. & Koss, M. C. (1975) Brainstem loci for activation of electrodermal response in the cat. American Journal of Physiology, 229, 930–4.Google Scholar
Fielding, S. & Lal, H. (1978) Neuroleptics and schizophrenia. In Handbook of Psychopharmacology (eds. Iverson, L. L., Iverson, S. D. and Snyder, S. H.). Vol. 10. New York: Plenum Press, pp 91–128.Google Scholar
Garvey, H. L. & Ram, N. (1975a) Comparative antihypertensive effects and tissue distribution of beta-adrenergic blocking drugs. Journal of Pharmacology and Experimental Therapeutics, 194, 220–33.Google Scholar
Garvey, H. L. & Ram, N. (1975b) Cortically induced hypertensive effects of beta-adrenergic blocking drugs. European Journal of Pharmacology, 33, 283–94.Google Scholar
Gruzelier, J. H. (1978) Propranolol acts to modulate autonomic orienting and habituation processes in schizophrenia. In Propranolol and Schizophrenia (eds. Roberts, E. and Amacher, P.). New York: A. R. Liss, 59–82.Google Scholar
Gruzelier, J. H. (1979) Lateral asymmetries in electrodermal activity and psychosis. In Hemisphere Asymmetries of Function in Psychopathology (eds. Gruzelier, J. H. and Flor-Henry, P.). Amsterdam: Elsevier/North Holland, 149–168.Google Scholar
Gruzelier, J. H. & Yorkston, N. J. (1978) Propranolol and schizophrenia: objective evidence of efficacy. Biological Basis of Schizophrenia (eds. W. and Hemmings, G.). Lancaster: MTP Press, 127–46.Google Scholar
Gruzelier, J. H. & Connolly, J. F. (1980) Differential actions of a pharmacological agent on electrodermal orienting responses as distinct from non-specific responses and electrodermal levels. In The Orienting Reflex in Humans (ed. Kimmel, H. D.). New York: Erlbaum, 701–713.Google Scholar
Gruzelier, J. H., Hirsch, S. R., Weller, M. & Murphy, C. (1979) The influence of D- or DL-propranolol and chlorpromazine on habituation of phasic electrodermal responses in schizophrenia. Acta Psychiatrica Scandinavia, 60, 241–8.CrossRefGoogle ScholarPubMed
Hollander, M. & Wolfe, D. A. (1973) Nonparametric Statistical Methods. London: Wiley.Google Scholar
Janssen, P. A. J., Neimegeers, C. J. E. & Schellenbens, K. H. L. (1965) Is it possible to predict the clinical effects of neuroleptic drugs from animal data? Arzneimittel Forschung, 15, 104–17.Google Scholar
Massuoka, D. & Hansson, E. (1968) Autoradiographic distribution studies of adrenergic blocking agents. II. 14C-Propranolol, a β-receptor type blocker. Acta Pharmacologica (Kbh), 25, 447.CrossRefGoogle Scholar
Overall, J. E. & Gorham, D. R. (1962) The brief psychiatric rating scale. Psychological Reports, 10, 799.Google Scholar
Pribram, K. H. & McGuinness, D. (1975) Arousal, activation and effort in the control of attention. Psychological Review, 82, 116.CrossRefGoogle ScholarPubMed
Ram, N., Hesse, U. C. & Heilmain, R. D. (1977) The effects of propranolol HCl in hippocampal-lesioned rats. Archives of International Pharmacodynamics, 229, 138–43.Google ScholarPubMed
Richardson, J. S. (1974) Basic concepts of psycho-pharmacological research as applied to the psycho-pharmacological analysis of the amygdala. Acta Neurobiologiae Experimentalis, 34, 543.Google Scholar
Shepperd, G. P. (1979) High dose propranolol in schizophrenia. British Journal of Psychiatry, 134, 470–6.Google Scholar
Van Zerssen, D. (1976) Beta-adrenergic blocking agents in the treatment of psychoses. Advances in Clinical Pharmacology, 12, 105–14.Google Scholar
Wang, G. N. (1964) The Neural Control of Sweating. Madison: University of Wisconsin Press.Google Scholar
Wing, J. K., Cooper, J. E. & Sartorius, N. (1974) Measurement and Classification of Psychiatric Symptoms. London: Cambridge University Press.Google Scholar
Yorkston, N. J., Zaki, S. A., Themen, J. F. A. & Havard, C. W. H. (1976) Propranolol to control schizophrenic symptoms: 55 patients. Advances in Clinical Pharmacology, 12, 91–104.Google Scholar
Yorkston, N. J., Zaki, S. A., Malik, M. K. U., Morrison, R. C. & Havard, C. W. H. (1974) Propranolol in the control of schizophrenic symptoms. British Medical Journal, iv, 633–5.Google Scholar
Yorkston, N. J., Gruzelier, J. H., Zaki, S. A., Hollander, D., Pitcher, D. & Sergeant, N. S. (1977) Propranolol as an adjunct to the treatment of schizophrenia. Lancet, i, 575.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.